Compare BRSP & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRSP | LXRX |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 738.7M | 703.3M |
| IPO Year | 2017 | 2000 |
| Metric | BRSP | LXRX |
|---|---|---|
| Price | $5.55 | $1.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $6.50 | $4.15 |
| AVG Volume (30 Days) | 849.8K | ★ 3.2M |
| Earning Date | 04-28-2026 | 05-01-2026 |
| Dividend Yield | ★ 11.03% | N/A |
| EPS Growth | 75.24 | ★ 77.78 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $330,587,000.00 | $49,803,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.54 | N/A |
| P/E Ratio | $185.67 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $4.84 | $0.64 |
| 52 Week High | $6.17 | $2.53 |
| Indicator | BRSP | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.68 | 44.54 |
| Support Level | $5.44 | $1.52 |
| Resistance Level | $6.00 | $1.95 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 26.39 | 17.35 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.